| Literature DB >> 32252345 |
Catarina Pimpão1,2, Inês V da Silva1,2, Andreia F Mósca1,2, Jacinta O Pinho1,3, Maria Manuela Gaspar1,3, Nadiia I Gumerova4, Annette Rompel4, Manuel Aureliano5, Graça Soveral1,2.
Abstract
Polyoxometalates (POMs) are of increasing interest due to their proven anticancer activities. Aquaporins (AQPs) were found to be overexpressed in tumors bringing particular attention to their inhibitors as anticancer drugs. Herein, we report for the first time the ability of polyoxotungstates (POTs), such as of Wells-Dawson P2W18, P2W12, and P2W15, and Preyssler P5W30 structures, to affect aquaporin-3 (AQP3) activity and impair melanoma cell migration. The tested POTs were revealed to inhibit AQP3 function with different effects, with P2W18, P2W12, and P5W30 being the most potent (50% inhibitory concentration (IC50) = 0.8, 2.8, and 3.2 µM), and P2W15 being the weakest (IC50 > 100 µM). The selectivity of P2W18 toward AQP3 was confirmed in yeast cells transformed with human aquaglyceroporins. The effect of P2W12 and P2W18 on melanoma cells that highly express AQP3 revealed an impairment of cell migration between 55% and 65% after 24 h, indicating that the anticancer properties of these compounds may in part be due to the blockage of AQP3-mediated permeability. Altogether, our data revealed that P2W18 strongly affects AQP3 activity and cancer cell growth, unveiling its potential as an anticancer drug against tumors where AQP3 is highly expressed.Entities:
Keywords: aquaglyceroporin; aquaporin; cancer; glycerol; inhibitors; melanoma; polyoxotungstates
Mesh:
Substances:
Year: 2020 PMID: 32252345 PMCID: PMC7177757 DOI: 10.3390/ijms21072467
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Polyhedral representation of polyoxotungstate (POT) structures tested in this study. (A) Wells–Dawson anion [P2W18O62]6− (P2W18); (B) tri-lacunary Wells–Dawson anion [P2W15O56]12− (P2W15); (C) hexa-lacunary Wells–Dawson anion [H2P2W12O48]12− (P2W12); (D) Preyssler anion [NaP5W30O110]14− (P5W30). Color code: {WO6}, mint; P, yellow; O, red; Na, blue.
Figure 2Effect of POTs on human red blood cell (hRBC) membrane permeability. (A) Representative stopped-flow signal showing changes in light scattering intensity when cells are confronted with a hyperosmotic glycerol solution. After a first shrinkage due to water efflux, cells reswell due to glycerol entrance via aquaporin 3 (AQP3) (control). Cell treatment with P2W18 prevents glycerol influx. (B) Water and glycerol permeability of hRBCs incubated with POTs (100 µM for 30 min). (C) Dose–response curves of glycerol permeability inhibition by POTs. Data are shown as means ± SD of three independent experiments. ns, non-significant; * p < 0.05; ** p < 0.01; *** p < 0.001. * treated vs. non-treated cells.
Maximal inhibition and 50% inhibitory concentration (IC50) values of AQP3 glycerol permeability inhibition by POTs.
| POTs | Glycerol Permeability | |
|---|---|---|
| Max Inhibition (%) | IC50 (µM) | |
| P2W12 | 86.40 ± 7.91 | 2.78 ± 0.09 |
| P2W15 | 46.47 ± 4.18 | >100 |
| P2W18 | 99.24 ± 0.03 | 0.80 ± 0.04 |
| P5W30 | 99.31 ± 0.14 | 3.24 ± 0.03 |
Figure 3Effect of P2W18 on human aquaglyceroporins expressed in yeast. (A) Change in relative cell volume of AQP3-expressing cells challenged with a glycerol osmotic gradient. (B) Glycerol permeability (Pgly) of yeast cells transformed with the empty vector (control) or expressing human AQP3, AQP7, or AQP9, non-treated and treated with 100 µM P2W18 for 30 min. Data are shown as means ± SD of three independent experiments. *** p < 0.001, treated vs. non-treated cells.
Figure 4Screening AQPs expression in human melanoma cells. AQP messenger RNA (mRNA) expression in MNT-1 cells normalized to the mean of two housekeeping genes, HTRP-1 and β-actin, showing AQP3 as the most expressed isoform. Data represent means ± SD of three independent experiments. n.d., not detected.
Figure 5Effect of POTs on viability and migration of human melanoma cells. (A) Cell viability determined by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazium bromide (MTT) assay after cell exposure to a range of the four POT concentrations for 24 h. (B) Wound closure progression in cells non-treated (control) and treated with 5 µM POTs at 0, 3, 6, 9, and 24 h. (C) Cell migration of cells non-treated and treated with 5 µM POTs. Results are expressed as means ± SD of three independent experiments. * p < 0.05, *** p < 0.001, treated vs. non-treated cells and between POTs.
POTs used in this study.
| Formula | Abbreviation | Net Charge | Charge Density (Charge/Number of Addenda Atoms Ratio) | Synthesized According to | First Structural Report in | 31P-NMR Signals Assignment |
|---|---|---|---|---|---|---|
| K6[α-P2W18O62]·14H2O | P2W18 | −6 | 0.33 | [ | [ | [ |
| K12[α-H2P2W12O48]·16H2O | P2W12 | −12 | 1 | [ | [ | [ |
| Na12[α-P2W15O56]·24H2O | P2W15 | −12 | 0.8 | [ | [ | [ |
| (NH4)14[NaP5W30O110] 31H2O | P5W30 | −14 | 0.47 | [ | [ | [ |